Sign Up
OverviewAPI
Adagene Inc. advances clinical collaboration development program for anti-CTLA-4 SAFEbody ADG126 in combination with Merck & Co., Inc.'s anti-PD-1 therapy, KEYTRUDA. The company has initiated evaluation at 20 mg/kg loading doses in combination with pembrolizumab and received clearance from China’s Center for Drug Evaluation. The updates include data from ongoing phase 1b/2 clinical trials and the initiation of evaluation at 20 mg/kg loading doses in combination with pembrolizumab.

Ask a question